North Carolina-based Cirrus Pharmaceuticals has announced that it will be investing in a new flexible cGMP suite at its facility in Research Triangle Park, NC and will offer new manufacturing services beginning next year. In July 2013, Cirrus announced that it had been acquired by Kemwell Biopharma. The company currently offers a number of analytical and development services for OINDPs.
Kemwell President of R&D Ninad Deshpanday commented, “With this investment, we are bringing our customers a new service from our US facility. We will offer our clients cGMP manufacturing services for many dosage forms including inhalation, liquids, topicals and oral solids. This service will enable our clients to enter clinic faster. We have completed the design phase and expect the suite to be ready to service customers by April 2015.”
Read the Cirrus press release.
